Business Description
BeyondSpring Inc
NAICS : 325411
SIC : 2833
Description
BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities that may provide multiple therapeutic opportunities. Plinabulin has increased the survival of neutrophils, a type of white blood cell important in the prevention of bacterial infections. The Company has a scalable business model integrating clinical resources in the United States and China.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 20.24 | |||||
| Equity-to-Asset | 0.33 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -7.2 | |||||
| Beneish M-Score | 2.77 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 13.3 | |||||
| 3-Year EPS without NRI Growth Rate | 12.2 | |||||
| 3-Year FCF Growth Rate | 10.2 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 17.94 | |||||
| 9-Day RSI | 21.66 | |||||
| 14-Day RSI | 27.29 | |||||
| 6-1 Month Momentum % | -40 | |||||
| 12-1 Month Momentum % | -91.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.96 | |||||
| Quick Ratio | 4.96 | |||||
| Cash Ratio | 4.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -4903.03 | |||||
| Net Margin % | -4750.48 | |||||
| ROE % | -114.13 | |||||
| ROA % | -67.32 | |||||
| ROIC % | -743.2 | |||||
| ROC (Joel Greenblatt) % | -2610.86 | |||||
| ROCE % | -80.69 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 26.37 | |||||
| PB Ratio | 1.38 | |||||
| Price-to-Tangible-Book | 1.43 | |||||
| EV-to-EBIT | 0.5 | |||||
| EV-to-Forward-EBIT | -0.04 | |||||
| EV-to-EBITDA | 0.5 | |||||
| EV-to-Forward-EBITDA | -0.04 | |||||
| EV-to-Revenue | -23.53 | |||||
| EV-to-Forward-Revenue | 1.19 | |||||
| EV-to-FCF | 0.62 | |||||
| Price-to-Net-Current-Asset-Value | 1.9 | |||||
| Price-to-Net-Cash | 2.2 | |||||
| Earnings Yield (Greenblatt) % | 201.61 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BYSI
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.351 | ||
| EPS (TTM) ($) | -1.64 | ||
| Beta | 0.93 | ||
| Volatility % | 64.01 | ||
| 14-Day RSI | 27.29 | ||
| 14-Day ATR ($) | 0.110672 | ||
| 20-Day SMA ($) | 1.265235 | ||
| 12-1 Month Momentum % | -91.62 | ||
| 52-Week Range ($) | 0.92 - 17.98 | ||
| Shares Outstanding (Mil) | 38.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BeyondSpring Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
BeyondSpring Inc Analysis
Share your researchHeadlines
See More
No news.